Alector, Inc. (NASDAQ:ALEC) Receives $4.17 Average PT from Analysts

Alector, Inc. (NASDAQ:ALEC) has received an average recommendation of “Hold” from the eight analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $4.1667.

A number of research analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a report on Wednesday, January 21st. Cantor Fitzgerald upgraded shares of Alector from a “neutral” rating to an “overweight” rating in a report on Wednesday. Wall Street Zen cut shares of Alector from a “hold” rating to a “sell” rating in a research report on Sunday, March 1st. BTIG Research upgraded shares of Alector from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research note on Tuesday, March 10th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of Alector in a research report on Thursday, January 8th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALEC. Foresite Capital Management IV LLC purchased a new position in shares of Alector during the fourth quarter valued at $6,064,000. Balyasny Asset Management L.P. purchased a new stake in Alector in the fourth quarter worth about $5,094,000. 683 Capital Management LLC grew its holdings in Alector by 235.0% during the 4th quarter. 683 Capital Management LLC now owns 3,350,000 shares of the company’s stock worth $5,226,000 after acquiring an additional 2,350,000 shares in the last quarter. Ikarian Capital LLC grew its holdings in Alector by 174.0% during the 4th quarter. Ikarian Capital LLC now owns 2,082,606 shares of the company’s stock worth $3,249,000 after acquiring an additional 1,322,606 shares in the last quarter. Finally, Spruce Street Capital LP purchased a new position in Alector during the 4th quarter valued at about $1,744,000. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Alector Price Performance

Shares of ALEC stock opened at $2.55 on Friday. The stock has a 50 day moving average price of $2.19 and a 200 day moving average price of $1.94. Alector has a 52-week low of $0.90 and a 52-week high of $3.40. The company has a debt-to-equity ratio of 0.30, a quick ratio of 3.83 and a current ratio of 3.83. The firm has a market capitalization of $281.42 million, a P/E ratio of -1.83 and a beta of 0.58.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.05. Alector had a negative return on equity of 224.96% and a negative net margin of 679.16%.The company had revenue of $6.24 million for the quarter, compared to the consensus estimate of $1.78 million. As a group, sell-side analysts predict that Alector will post -1.88 earnings per share for the current year.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.